Effect of GLP-1 receptor agonists on waist circumference among type 2 diabetes patients: a systematic review and network meta-analysis

Endocrine

Volumn 48, Issue 3, 2015, Pages 794-803

  Sun, Feng ^a,b   Wu, Shanshan ^a   Guo, Shuxia ^b   Yu, Kai ^c   Yang, Zhirong ^a,d   Li, Lishi ^a,e   Zhang, Yuan ^a   Ji, Linong ^f   Zhan, Siyan ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b SHIHEZI UNIVERSITY   (China)

^c TIANJIN FIFTH CENTRAL HOSPITAL   (China)

^d SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

^e Och Spine at New York Presbyterian Hospitals   (United States)

^f PEKING UNIVERSITY   (China)

Author keywords

GLP 1 receptor agonists; Network meta analysis; Type 2 diabetes; Waist circumference

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INSULIN; LIRAGLUTIDE; PLACEBO; SITAGLIPTIN; TASPOGLUTIDE; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; PEPTIDE; VENOM;

ARTICLE; DIABETIC PATIENT; DISEASE DURATION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; HUMAN; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROBABILITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT DURATION; WAIST CIRCUMFERENCE; AGONISTS; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HUMANS; HYPOGLYCEMIC AGENTS; LIRAGLUTIDE; PEPTIDES; TREATMENT OUTCOME; VENOMS; WAIST CIRCUMFERENCE;

EID: 84925679919     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-014-0373-0     Document Type: Article

References (51)

1. K.B. Hansen, F.K. Knop, J.J. Holst, T. Vilsbøll, Treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists. Int. J. Clin. Pract. 63, 1154–1160 (2009)
2. S. Goykhman, A. Drincic, J.C. Desmangles, M. Rendell, Insulin Glargine: A review 8 years after its introduction. Expert Opin. Pharmacother. 10, 705–718 (2009)
3. M.A. Nauck, M.M. Heimesaat, K. Behle, J.J. Holst, M.S. Nauck, R. Ritzel, M. Hüfner, W.H. Schmiegel, Effects of glucagon-like peptide 1 on counter regulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J. Clin. Endocrinol. Metab. 87, 1239–1246 (2002)
4. T. Vilsbøll, T. Krarup, S. Madsbad, J.J. Holst, Both GLP-l and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regul. Pept. 114, 115–121 (2003)
5. M. Zander, S. Madsbad, J.L. Madsen, J.J. Holst, Effect of 6-week course of glucagon-like peptide-1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: A parallel-group study. Lancet 359, 824–830 (2002)
6. E. Wajcberg, A. Tavaria, Exenaride: clinical aspects of the first incretin-mimetic for the treatment of type 2 diabetes mellitus. Expert Opin. Pharmacother. 10, 135–142 (2009)
7. J.J. Neumiller, R.K. Campbell, Liraglutide: a once-daily incretin mimetic for the treatment of type 2 diabetes mellitus. Ann. Pharmacother. 43, 1433–1444 (2009)
8. C.E. Ezenwaka, O. Okoye, C. Esonwune, P. Onuoha, C. Dioka, C. Osuji, C. Oguejiofor, S. Meludu, High Prevalence of Abdominal Obesity Increases the Risk of the Metabolic Syndrome in Nigerian Type 2 Diabetes Patients: Using the International Diabetes Federation Worldwide Definition. Metab. Syndr. Relat. Disord. 12, 277–282 (2014)
9. R. Bhushan, K.E. Elkind-Hirsch, M. Bhushan, W.J. Butler, K. Duncan, O. Marrioneaux, Improved glycemic control and reduction of cardiometabolic risk factors in subjects with type 2 diabetes and metabolic syndrome treated with exenatide in a clinical practice setting. Diabetes Technol. Ther. 11, 353–359 (2009)
10. J.A. Beckman, M.A. Creager, P. Libby, Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 287, 2570–2581 (2002)
11. H.M. Lakka, D.E. Laaksonen, T.T. Lakka, The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288, 2709–2716 (2002)
12. P.W. Wilson, R.B. D’Agostino, H. Parise, L. Sullivan, J.B. Meigs, Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 112, 3066–3072 (2005)
13. H. Nagao, S. Kashine, H. Nishizawa, T. Okada, T. Kimura, A. Hirata, S. Fukuda, J. Kozawa, N. Maeda, T. Kitamura, T. Yasuda, K. Okita, T. Hibuse, M. Tsugawa, A. Imagawa, T. Funahashi, I. Shimomura, Vascular complications and changes in body mass index in Japanese type 2 diabetic patients with abdominal obesity. Cardiovasc. Diabetol. 12, 88 (2013)
14. R.R. Wing, B. Marquez, Behavioral aspects of weight loss in type 2 diabetes. Curr. Diab. Rep. 8, 126–131 (2008)
15. G. Van Valkenhoef, G. Lu, B. de Brock, H. Hillege, A.E. Ades, J. Nicky, Welton Automating network meta-analysis. Res. Synth. Methods 3, 285–299 (2012)
16. A.R. Jadad, R.A. Moore, D. Carroll, C. Jenkinson, D.J. Reynolds, D.J. Gavaghan, H.J. McQuay, Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control. Clin. Trials 17, 1–12 (1996)
17. R. DerSimonian, N. Laird, Meta-analysis in clinical trials. Control. Clin. Trials 7, 177–188 (1986)
18. J.P. Higgins, S.G. Thompson, Quantifying heterogeneity in a meta-analysis. Stat. Med. 21, 1539–1558 (2002)
19. G. Lu, A.E. Ades, Combination of direct and indirect evidence in mixed treatment comparisons. Stat. Med. 23, 3105–3124 (2004)
20. G. Salanti, A.E. Ades, J.P. Ioannidis, Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J. Clin. Epidemiol. 64, 163–171 (2011)
21. Spiegelhalter D.J., Best N.G., Carlin B.P., Van Der Linde A.: Bayesian measures of model complexity an fit. J. Royal. Stat. Soci.: Series B (Statistical Methodology) 64, 583–639 (2002)
22. F. Song, D.G. Altman, A.M. Glenny, J.J. Deeks, Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 326, 472 (2003)
23. Apovian C.M., Bergenstal R.M., Cuddihy R.M., Qu Y., Lenox S., Lewis M.S., Glass L.C.: Effects of exenatide combined with lifestyle modification in patients with type 2 Diabetes. Am. J. Med. 123, 468.e9–e17 (2010)
24. J.B. Buse, R.M. Bergenstal, L.C. Glass, C.R. Heilmann, M.S. Lewis, A.Y. Kwan, B.J. Hoogwerf, J. Rosenstock, Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann. Intern. Med. 154, 103–112 (2011)
25. M. Diamant, L. Van Gaal, S. Stranks, B. Guerci, L. MacConell, H. Haber, J. Scism-Bacon, M. Trautmann, Safety and efficacy of once-weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes over 84 weeks. Diabetes Care 35, 683–689 (2012)
26. M. Davies, S. Heller, S. Sreenan, H. Sapin, O. Adetunji, A. Tahbaz, J. Vora, Once-weekly exenatide versus once- or twice-daily insulin detemir: randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas. Diabetes Care 36, 1368–1376 (2013)
27. M.J. Davies, R. Donnelly, A.H. Barnett, S. Jones, C. Nicolay, A. Kilcoyne, Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: Results of the helping evaluate exenatide in patients with diabetes compared with long-acting insulin (HEELA) study. Diabetes Obes. Metab. 11, 1153–1162 (2009)
28. R.A. DeFronzo, C. Triplitt, Y. Qu, M.S. Lewis, D. Maggs, L.C. Glass, Effects of exenatide plus rosiglitazone on (beta)-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin. Diabetes Care 33, 951–957 (2010)
29. G. Derosa, I.G. Franzetti, F. Querci, A. Carbone, L. Ciccarelli, M.N. Piccinni, E. Fogari, P. Maffioli, Variation in inflammatory markers and glycemic parameters after 12 months of exenatide plus metformin treatment compared with metformin alone: a randomized placebo-controlled trial. Pharmacotherapy 33, 817–826 (2013)
30. T. Forst, G. Michelson, F. Ratter, M.M. Weber, S. Anders, M. Mitry, B. Wilhelm, A. Pfützner, Addition of liraglutide in patients with Type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function. Diabet. Med. 29, 1115–1118 (2012)
31. H. Harder, L. Nielsen, D.T. Tu, A. Astrup, The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes. Diabetes Care 27, 1915–1921 (2004)
32. T. Kadowaki, M. Namba, T. Imaoka, A. Yamamura, W. Goto, M.K. Boardman, H. Sowa, Improved glycemic control and reduced bodyweight with exenatide: A double-blind, randomized, phase 3 study in Japanese patients with suboptimally controlled type 2 diabetes over 24 weeks. J. Diabetes Invest. 2, 210–217 (2011)
33. C.J. Li, J. Li, Q.M. Zhang, L. Lv, R. Chen, C.F. Lv, P. Yu, D.M. Yu, Efficacy and safety comparison between liraglutide as add-on therapy to insulin and insulin dose-increase in Chinese subjects with poorly controlled type 2 diabetes and abdominal obesity. Cardiovasc. Diabetol. 11, 142 (2012)
34. J. Liutkus, Rosas Guzman J., Norwood P., Pop L., Northrup J., Cao D., Trautmann M.: A placebo-controlled trial of exenatide twice-daily added to thiazolidinediones alone or in combination with metformin. Diabetes. Obes. Metab. 12, 1058–1065 (2010)
35. R. Pratley, M. Nauck, T. Bailey, E. Montanya, R. Cuddihy, S. Filetti, A. Garber, A.B. Thomsen, H. Hartvig, M. Davies, 1860-LIRA-DPP-4 Study Group: One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: A randomised, parallel-group, open-label trial. Int. J. Clin. Pract. 65, 397–407 (2011)
36. I. Raz, V. Fonseca, M. Kipnes, L. Durrwell, J. Hoekstra, M. Boldrin, R. Balena, Efficacy and safety of taspoglutide monotherapy in drug-naive type 2 diabetic patients after 24 weeks of treatment: results of a randomized, double-blind, placebo-controlled phase 3 study (T-emerge 1). Diabetes Care 35, 485–487 (2012)
37. R.R. Henry, S. Mudaliar, L. Kanitra, M. Woloschak, R. Balena, T-Emerge 3 Study Group: Efficacy and safety of taspoglutide in patients with type 2 diabetes inadequately controlled with metformin plus pioglitazone over 24 weeks: T-emerge 3 trial. J. Clin. Endocrinol. Metab. 97, 2370–2379 (2012)
38. R.E. Pratley, D. Urosevic, M. Boldrin, R. Balena, T-emerge 6 Study Group: Efficacy and tolerability of taspoglutide versus pioglitazone in subjects with type 2 diabetes uncontrolled with sulphonylurea or sulphonylurea-metformin therapy: A randomized, double-blind study (T-emerge 6). Diabetes Obes. Metab. 15, 234–240 (2013)
39. P. Hollander, B. Lasko, A.H. Barnett, M. Bengus, L. Kanitra, F.X. Pi-Sunyer, R. Balena, Effects of taspoglutide on glycemic control and body weight in obese patients with type 2 diabetes (T-emerge 7 study). Obesity (Silver Spring) 21, 238–247 (2013)
40. D. Mundil, A. Cameron-Vendrig, M. Husain, GLP-1 receptor agonists: a clinical perspective on cardiovascular effects. Diab. Vasc. Dis. Res. 9, 95–108 (2012)
41. D. Lorber, GLP-1 receptor agonists: effects on cardiovascular risk reduction. Cardiovasc. Ther. 31, 238–249 (2013)
42. M. Buysschaert, V. Preumont, P.R. Oriot, I. Paris, M. Ponchon, D. Scarnière, P. Selvais, UCL Study Group for Exenatide: One-year metabolic outcomes in patients with type 2 diabetes treated with exenatide in routine practice. Diabetes Metab. 36, 381–388 (2010)
43. M.C. Bunck, M. Diamant, B. Eliasson, A. Cornér, R.M. Shaginian, R.J. Heine, M.R. Taskinen, H. Yki-Järvinen, U. Smith, Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition. Diabetes Care 33, 1734–1737 (2010)
44. Y. Matsuzawa, T. Funahashi, T. Nakamura, The concept of metabolic syndrome: contribution of visceral fat accumulation and its molecular mechanism. J Atheroscler. Thromb. 18, 629–639 (2011)
45. H. Yanai, H. Adachi, H. Hamasaki, Y. Masui, R. Yoshikawa, S. Moriyama, S. Mishima, A. Sako, Effects of 6-month sitagliptin treatment on glucose and lipid metabolism, blood pressure, body weight and renal function in type 2 diabetic patients: a chart-based analysis. J. Clin. Med. Res. 4, 251–258 (2012)
46. S. Brunton, GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other? Int. J. Clin. Pract. 68, 557–567 (2014)
47. J. Jendle, M.A. Nauck, D.R. Matthews, A. Frid, K. Hermansen, M. Düring, M. Zdravkovic, B.J. Strauss, A.J. Garber, LEAD-2 and LEAD-3 Study Groups: Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes. Metab. 11, 1163–1172 (2009)
48. L. van Bloemendaal, J.S. Ten Kulve, S.E. la Fleur, R.G. Ijzerman, M. Diamant, Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS. J. Endocrinol. 221, T1–T16 (2014)
49. Y. Li, T. Perry, M.S. Kindy, B.K. Harvey, D. Tweedie, H.W. Holloway, K. Powers, H. Shen, J.M. Egan, K. Sambamurti, A. Brossi, D.K. Lahiri, M.P. Mattson, B.J. Hoffer, Y. Wang, N.H. Greig, GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc. Natl. Acad. Sci. U.S.A. 106, 1285–1290 (2009)
50. P.L. McClean, V. Parthsarathy, E. Faivre, C. Holscher, The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer’s disease. J. Neurosci. 31, 6587–6594 (2011)
51. D.M. Caldwell, A.E. Ades, J.P. Higgins, Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 331, 897–900 (2005)